Literature DB >> 22504008

The unsurprising story of MDR-TB resistance in India.

Giridhara R Babu1, Ramanan Laxminarayan.   

Abstract

W.H.O. defines Totally Drug-Resistant Tuberculosis (TDR-TB) as Tuberculosis caused due to a virulent strain of tuberculosis that seems to be resistant to all known treatments. In a recent correspondence, Zarir F. Udwadia and others described what they termed as "first patients from India with TDR tuberculosis". The processes and weakness ingrained in the vastness of Indian society and health system leading to drug resistance reveal multitude layers of weakness. This review aims at listing some of the important factors and levels responsible for the development of resistance in TB. The review identifies access issues, poor adherence to short-course chemotherapy, poor knowledge, practices and quality TB drugs in the private sector, resistance against some of second-line drugs prevalent in India and poor utilization of diagnostic services as the factors for causing TB resistance in India.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22504008     DOI： 10.1016/j.tube.2012.02.009

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN： 1472-9792            Impact factor:   3.131


  10 in total

1.  Tuberculosis diagnosis and management in the public versus private sector: a standardised patients study in Mumbai, India.

Authors:  Jishnu Das; Madhukar Pai; Benjamin Daniels; Daksha Shah; Ada T Kwan; Ranendra Das; Veena Das; Varsha Puri; Pranita Tipre; Upalimitra Waghmare; Mangala Gomare; Padmaja Keskar
Journal:  BMJ Glob Health       Date:  2022-10

2.  Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis.

Authors:  Kristina Shigyo; Oksana Ocheretina; Yves Mary Merveille; Warren D Johnson; Jean William Pape; Carl F Nathan; Daniel W Fitzgerald
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

3.  In silico-based high-throughput screen for discovery of novel combinations for tuberculosis treatment.

Authors:  Ragini Singh; Vasanthi Ramachandran; Radha Shandil; Sreevalli Sharma; Swati Khandelwal; Malancha Karmarkar; Naveen Kumar; Suresh Solapure; Ramanatha Saralaya; Robert Nanduri; Vijender Panduga; Jitendar Reddy; K R Prabhakar; Swaminathan Rajagopalan; Narasimha Rao; Shridhar Narayanan; Anand Anandkumar; V Balasubramanian; Santanu Datta
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

4.  Drug-resistant tuberculosis in Mumbai, India: An agenda for operations research.

Authors:  Nerges Mistry; Monica Tolani; David Osrin
Journal:  Oper Res Health Care       Date:  2012-06

5.  Optimal Duration of Daily Antituberculosis Therapy before Switching to DOTS Intermittent Therapy to Reduce Mortality in HIV Infected Patients: A Duration-Response Analysis Using Restricted Cubic Splines.

Authors:  Gerardo Alvarez-Uria; Raghavakalyan Pakam; Manoranjan Midde; Praveen Kumar Naik
Journal:  Int Sch Res Notices       Date:  2014-12-15

6.  Providers' knowledge of diagnosis and treatment of tuberculosis using vignettes: evidence from rural Bihar, India.

Authors:  Manoj Mohanan; Jeremy D Goldhaber-Fiebert; Soledad Giardili; Marcos Vera-Hernández
Journal:  BMJ Glob Health       Date:  2016-12-16

7.  Structural basis for the in vitro known acyl-depsipeptide 2 (ADEP2) inhibition to Clp 2 protease from Mycobacterium tuberculosis.

Authors:  Natasha Khandekar; Snehal Singh; Ruchi Shukla; Sridevi Tirumalaraju; Srinivas Bandaru; Tushar Banerjee; Anuraj Nayarisseri
Journal:  Bioinformation       Date:  2016-06-21

8.  A humanized mouse model of tuberculosis.

Authors:  Veronica E Calderon; Gustavo Valbuena; Yenny Goez; Barbara M Judy; Matthew B Huante; Putri Sutjita; R Katie Johnston; D Mark Estes; Robert L Hunter; Jeffrey K Actor; Jeffrey D Cirillo; Janice J Endsley
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

9.  Effect of hyperglycaemia in pregnancy on adiposity in their infants in India: a protocol of a multicentre cohort study.

Authors:  Giridhara R Babu; Lavanya Garadi; G V S Murthy; Sanjay Kinra
Journal:  BMJ Open       Date:  2014-06-27       Impact factor: 2.692

10.  Directly-observed intermittent therapy versus unsupervised daily regimen during the intensive phase of antituberculosis therapy in HIV infected patients.

Authors:  Gerardo Alvarez-Uria; Manoranjan Midde; Raghavakalyan Pakam; Praveen Kumar Naik
Journal:  Biomed Res Int       Date:  2014-06-11       Impact factor: 3.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.